Phase I dose-escalation study of procaspase-activating compound-1 in combination with temozolomide in patients with recurrent high-grade astrocytomas.
Matthias HoldhoffM Kelly NicholasRichard A PetersonStefania MarakaLi C LiuJames H FischerJeffrey S WefelTimothy M FanTracy VannorsdallMeredith RussellMichaella IacoboniTheodore M TarasowPaul J HergenrotherArkadiusz Z DudekOana C DanciuPublished in: Neuro-oncology advances (2023)
/5 days per 28-day cycle. The maximum tolerated dose was not reached. Further dose escalation of PAC-1 in combination with TMZ is advised before conducting a formal prospective efficacy study in this patient population.